

Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	August 8, 2022	
TO:	All Healthcare Providers especially Gastroenterology, Internal Medicine, Nursing, and Pharmacy	
FROM:	University of Alberta Hospital (UAH), Special Chemistry Laboratory, Edmonton	
RE:	Infliximab Antibodies Test Temporarily Referred out to Prometheus Laboratories	

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

• **Effective immediately,** the Infliximab Antibodies test offered by the University of Alberta Hospital, Special Chemistry Laboratory in Edmonton will temporarily be referred out to Prometheus Laboratories in California.

Background

- On June 10, 2022, all infliximab antibody requests were routed to St Paul's Hospital Laboratory in BC due to technical challenges with reagents.
- Physicians have expressed concerns with the BC referral lab turnaround time of ~1 month.
- The University of Alberta Hospital, Special Chemistry Laboratory is unable to run and report the Infliximab Antibodies test until further notice. Work is underway to validate a new total infliximab antibody ELISA assay.

How this will impact you

- Blood collected into a **SERUM** gold or red top tube is the only acceptable sample type for infliximab level and infliximab antibody. Plasma lavender EDTA tubes will NOT BE ACCEPTED.
- The Special Chemistry Laboratory in Edmonton will continue to run and report the Infliximab Level.
- For subtherapeutic drug concentrations (Infliximab Level <3.0ug/mL), a comment will append: "Infliximab antibodies test referred out. Report to follow."
- Reflex testing for infliximab antibodies will be measured by a different method; a size exclusion chromatography mobility shift assay on a High Performance Liquid Chromatography (HPLC) system.

Infliximab Antibody Test	Reference Interval	Interpretation
EDM ELISA	<2 ug/mL	Dose optimize
Prometheus HPLC	<3.1 U/mL	Undetectable Antibodies to Infliximab

- The presence of detectable antibodies to infliximab is associated with a shorter half-life, increased clearance, and a shorter duration of response.
- The expected turnaround time for reported results is one week.
- Referral lab reports will be scanned into Epic but will not appear in Netcare. Physicians that are not on Connect Care will receive a paper copy of the report in the mail.

Action Required

A <u>complete</u> APL Infliximab Level Order Form signed by a specialist MUST be sent with the **SERUM** specimen. Incomplete forms may result in testing delays.

Questions/Concerns

Dr. Kareena Schnabl, Clinical Biochemist, (780) 407-3186, kareena.schnabl@aplabs.ca

Approved by

- Carolyn O'Hara, Interim Chief Medical Laboratory Officer, Alberta Precision Laboratories
- Hossein Sadrzadeh, Section Chief Biochemistry, Alberta Precision Laboratories, South Sector
- Paul Klonowski, Associate Medical Director, Alberta Precision Laboratories, South Sector